BerGenBio

Selective AXL inhibitors

CAREERS AT BERGENBIO

WORK WITH US

BerGenBio is a world leader in understanding AXL biology. We are focused on developing transformative drugs targeting AXL as a potential cornerstone therapy for aggressive diseases, including immune-evasive, therapy-resistant cancers, and severe respiratory infections. We are looking for talented individuals to join us on our journey. If you’re looking for an exciting, rewarding work environment and an opportunity to make a real difference in the lives of patients around the world, please consider applying to join our team.

BerGenBio’s headquarters are in Bergen, Norway and our highly experienced clinical development team are located in Oxford, UK, together with support functions

What is it like to work with us?

Our people are the key to realising our mission. We offer the opportunity to work with cutting edge science that has the potential to change patient lives in a fun, supportive environment which fosters teamwork creativity and leadership.

What we offer you

We value our people and provide a range of attractive and competitive benefits. We offer a competitive salary, excellent pension with life assurance, flexible working hours, free parking and opportunities for development within the role and progression of your career.

Equal Opportunities

We are an equal opportunities employer and ensure that all applications are treated appropriately and fairly and that, all things being equal, no candidate is rejected because of their age, gender, race, sexuality or any other protected characteristic.

HOW TO APPLY

To apply, please send your CV and a covering letter, including your current salary and package details, to
recruitment@bergenbio.com

We welcome applications directly from individuals but no agencies please.

Email Us

Subscribe to our newsletter

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.